These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24889065)

  • 1. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.
    Demicco EG; Boland GM; Brewer Savannah KJ; Lusby K; Young ED; Ingram D; Watson KL; Bailey M; Guo X; Hornick JL; van de Rijn M; Wang WL; Torres KE; Lev D; Lazar AJ
    Histopathology; 2015 Apr; 66(5):627-38. PubMed ID: 24889065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors.
    Robin YM; Penel N; Pérot G; Neuville A; Vélasco V; Ranchère-Vince D; Terrier P; Coindre JM
    Mod Pathol; 2013 Apr; 26(4):502-10. PubMed ID: 23174934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.
    Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H
    Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
    Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
    Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
    Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
    Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.
    de Leval L; Waltregny D; Boniver J; Young RH; Castronovo V; Oliva E
    Am J Surg Pathol; 2006 Mar; 30(3):319-27. PubMed ID: 16538051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas.
    Lee CH; Roh JW; Choi JS; Kang S; Park IA; Chung HH; Jeon YT; Kim JW; Park NH; Kang SB; Song YS
    Int J Gynecol Cancer; 2011 May; 21(4):668-72. PubMed ID: 21412163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.
    Beck AH; Lee CH; Witten DM; Gleason BC; Edris B; Espinosa I; Zhu S; Li R; Montgomery KD; Marinelli RJ; Tibshirani R; Hastie T; Jablons DM; Rubin BP; Fletcher CD; West RB; van de Rijn M
    Oncogene; 2010 Feb; 29(6):845-54. PubMed ID: 19901961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular leiomyosarcoma: Clinicopathology and immunohistochemistry with special reference to a unique smooth muscle phenotype.
    Matsuyama A; Hisaoka M; Hashimoto H
    Pathol Int; 2010 Mar; 60(3):212-6. PubMed ID: 20403047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
    Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
    Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From PTEN loss of expression to RICTOR role in smooth muscle differentiation: complex involvement of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas.
    Gibault L; Ferreira C; Pérot G; Audebourg A; Chibon F; Bonnin S; Lagarde P; Vacher-Lavenu MC; Terrier P; Coindre JM; Aurias A
    Mod Pathol; 2012 Feb; 25(2):197-211. PubMed ID: 22080063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups.
    Carvalho JC; Thomas DG; Lucas DR
    Cancer; 2009 Sep; 115(18):4186-95. PubMed ID: 19626649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of smooth muscle markers in so called malignant fibrous histiocytomas.
    Hasegawa T; Hasegawa F; Hirose T; Sano T; Matsuno Y
    J Clin Pathol; 2003 Sep; 56(9):666-71. PubMed ID: 12944549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
    Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
    Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases.
    Nicolas MM; Tamboli P; Gomez JA; Czerniak BA
    Hum Pathol; 2010 May; 41(5):663-71. PubMed ID: 20004935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinonasal smooth muscle cell tumors: a clinicopathologic and immunohistochemical analysis of 12 cases with emphasis on the low-grade end of the spectrum.
    Huang HY; Antonescu CR
    Arch Pathol Lab Med; 2003 Mar; 127(3):297-304. PubMed ID: 12653572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma.
    Oda Y; Miyajima K; Kawaguchi K; Tamiya S; Oshiro Y; Hachitanda Y; Oya M; Iwamoto Y; Tsuneyoshi M
    Am J Surg Pathol; 2001 Aug; 25(8):1030-8. PubMed ID: 11474287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
    Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
    J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smooth muscle differentiation identifies two classes of poorly differentiated pleomorphic sarcomas with distinct outcome.
    Pérot G; Mendiboure J; Brouste V; Velasco V; Terrier P; Bonvalot S; Guillou L; Ranchère-Vince D; Aurias A; Coindre JM; Chibon F
    Mod Pathol; 2014 Jun; 27(6):840-50. PubMed ID: 24287457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.
    Mills AM; Beck AH; Montgomery KD; Zhu SX; Espinosa I; Lee CH; Subramanian S; Fletcher CD; van de Rijn M; West RB
    Am J Surg Pathol; 2011 Apr; 35(4):583-9. PubMed ID: 21412072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.